Press release

Siemens Healthineers Hemoglobin A1c Test for Diagnosing and Monitoring Diabetes Now Available on the Atellica Solution

Published on May 15, 2019

1

Product availability varies by country.

2

Atellica CH A1c_E IFU. Siemens Healthcare Diagnostics Inc. 11111609_EN Rev. 01, 2019-01

3

The Atellica CH A1c_E assay is NGSP certified and an IFCC-standardized HbA1c assay that demonstrates < 5% change with most known Hb variants (HbC, HbD, HbE, HbS, and HbA2).

4

International Diabetes Federation. IDF Diabetes Atlas, 8th edn. Brussels, Belgium: International Diabetes Federation, 2017. http://www.diabetesatlas.org

Siemens Healthineers

Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. In fiscal 2017, which ended on September 30, 2017, Siemens Healthineers generated revenue of €13.8 billion and profit of €2.5 billion and has about 48,000 employees worldwide.